Maternal TSH-receptor antibodies predict fetal/neonatal hyperthyroidism in pregnancies with a history of Graves disease
The Journal of Clinical Endocrinology & Metabolism · 13.08.2026 · 111 (9) · e2161-e2170
DOI: 10.1210/clinem/dgag118 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 18.03.2026. Verfasst von Langeza Saleh und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynaecology, Division of Obstetrics and Prenatal Medicine, Erasmus Medical Center Rotterdam, 3015 CN Rotterdam, the Neth…. Hauptthemen laut MEDLINE: Autoantibodies, Fetal Diseases, Graves Disease, Hyperthyroidism. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Vereniging Academische Ziekenhuizen.
Abstract (Originalsprache)
Context
Transplacental transfer of thyrotropin receptor antibodies (TRAbs) during pregnancy may cause fetal/neonatal thyroid dysfunction. Current guidelines recommend a universal TRAb titer threshold, irrespective of gestational age or assay platform. However, evidence supporting trimester-specific and assay-specific thresholds is lacking.
Objective
This work aimed to determine whether trimester-specific TRAb levels predict fetal/neonatal thyroid dysfunction and to establish assay-specific cutoff values for clinical risk stratification.
Methods
In this prospective, multicenter, observational cohort study (2010-2023), maternal TRAb titers were measured using the TRAK human assay on the BRAHMS Kryptor Compact Plus analyzer. Settings were tertiary and secondary care centers (n = 44) across the Netherlands. Patients included women with a history of (n = 500) or active (n = 178) Graves disease. Main outcome measures included biochemically confirmed fetal/neonatal hyperthyroidism or hypothyroidism.
Results
Trimester-specific TRAb titer thresholds predicted risk with high accuracy. In women with a history of Graves disease (n = 500), trimester-specific cutoffs of 25-, 19-, and 6-fold the upper limit of normal (ULN) showed a negative predictive value of 100%. In women with active Graves (n = 178), cutoffs of 10-, 12-, and 10-fold the ULN showed sensitivities of 89%, 86%, and 83%. Neonatal hyperthyroidism occurred despite low or declining maternal TRAb levels in mothers treated with antithyroid drugs.
Conclusion
Trimester-specific TRAb thresholds were higher than the universal ULN multipliers commonly applied in clinical practice, and differed by gestational age and disease status. Application of a single ULN-based threshold titer across different TRAb assays may result in misclassification (ie, overestimation of fetal and neonatal Graves disease) and consequently in unnecessary and resource-intensive fetal surveillance. This indicates that TRAb thresholds are assay specific and require platform-specific clinical validation, even when assays are calibrated against a common international standard.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics and Gynaecology, Division of Obstetrics and Prenatal Medicine, Erasmus Medical Center Rotterdam, 3015 CN Rotterdam, the Netherlands.
- Department of Immunology, Laboratory Medical Immunology, Erasmus Medical Center Rotterdam, 3015 CN Rotterdam, the Netherlands.
- Department of Cardiology, Thorax Center, Erasmus Medical Center Rotterdam, 3015 CN Rotterdam, the Netherlands.
- Department of Immunology, Erasmus Medical Center Rotterdam, 3015 CN Rotterdam, the Netherlands.
- Department of Endocrinology, Sophia Children's Hospital, Erasmus Medical Center, 3015 CN Rotterdam, the Netherlands.
- Department of Internal Medicine, Division of Pharmacology and Vascular Medicine, Erasmus Medical Center Rotterdam, 3015 CN Rotterdam, the Netherlands.
ORCID-Profile: Langeza Saleh
Förderung
- Vereniging Academische Ziekenhuizen
Zitieren
APA
Saleh, L., Schreurs, M. W. J., Boersma, E., Drexhage, H. A., de Muinck Keizer-Schrama, S. M. P. F., & Visser, W. (2026). Maternal TSH-receptor antibodies predict fetal/neonatal hyperthyroidism in pregnancies with a history of Graves disease. The Journal of Clinical Endocrinology & Metabolism, 111(9), e2161-e2170. https://doi.org/10.1210/clinem/dgag118
Vancouver
Saleh L, Schreurs MWJ, Boersma E, Drexhage HA, de Muinck Keizer-Schrama SMPF, Visser W. Maternal TSH-receptor antibodies predict fetal/neonatal hyperthyroidism in pregnancies with a history of Graves disease. The Journal of Clinical Endocrinology & Metabolism. 2026;111(9):e2161-e2170. doi:10.1210/clinem/dgag118
BibTeX
@article{Saleh2026,
author = {Saleh, Langeza and Schreurs, Marco W J and Boersma, Eric and Drexhage, Hemmo A and de Muinck Keizer-Schrama, Sabine M P F and Visser, Willy},
title = {Maternal TSH-receptor antibodies predict fetal/neonatal hyperthyroidism in pregnancies with a history of Graves disease},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2026},
volume = {111},
number = {9},
pages = {e2161--e2170},
doi = {10.1210/clinem/dgag118}
}
EUVIMED